From a research perspective, Alzheimer’s disease is defined as the presence of abnormal biomarkers of amyloid-β (Aβ) and tau, which constitute the biological hallmarks of the disease.1 Individuals with altered Aβ biomarkers but normal tau biomarkers are defined as to show ‘Alzheimer’s pathological change’, which is considered the earliest phase of the ‘Alzheimer’s continuum’. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.